These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1981190)

  • 21. Dopaminergic regulation of cortical acetylcholine release: effects of dopamine receptor agonists.
    Day J; Fibiger HC
    Neuroscience; 1993 Jun; 54(3):643-8. PubMed ID: 8101359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of SCH 39166, a novel dopamine D1 receptor antagonist, on [3H]acetylcholine release in rat striatal slices.
    Tedford CE; Crosby G; Iorio LC; Chipkin RE
    Eur J Pharmacol; 1992 Feb; 211(2):169-76. PubMed ID: 1535318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the D1 receptor agonist SKF 38393 on some behavioural effects of apomorphine in rats.
    Zarkovsky AM; Cereska KS
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr; 339(4):383-6. PubMed ID: 2567965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional antagonism of D-1 and D-2 dopaminergic mechanisms affecting striatal acetylcholine release.
    Gorell JM; Czarnecki B; Hubbell S
    Life Sci; 1986 Jun; 38(24):2247-54. PubMed ID: 2940433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. D1-dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour.
    Robertson HA; Peterson MR; Murphy K; Robertson GS
    Brain Res; 1989 Dec; 503(2):346-9. PubMed ID: 2532558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopaminergic modulation of striatal acetylcholine release in rats depleted of dopamine as neonates.
    Johnson BJ; Bruno JP
    Neuropharmacology; 1995 Feb; 34(2):191-203. PubMed ID: 7617145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increases in striatal acetylcholine by SKF-38393 are mediated through D1 dopamine receptors in striatum and not the frontal cortex.
    Zocchi A; Pert A
    Brain Res; 1993 Nov; 627(2):186-92. PubMed ID: 8298961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems.
    Singh NA; Bush LG; Gibb JW; Hanson GR
    Brain Res; 1992 Feb; 571(2):260-4. PubMed ID: 1351780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
    Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of dopaminergic terminal excitability by D1 selective agents: further characterization.
    Diana M; Young SJ; Groves PM
    Neuroscience; 1991; 42(2):441-9. PubMed ID: 1680226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CY 208-243 behaves as a typical D-1 agonist in the reserpine-treated mouse.
    Abbott B; Starr BS; Starr MS
    Pharmacol Biochem Behav; 1991 Feb; 38(2):259-63. PubMed ID: 1676166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of a delta opioid receptor agonist but not a mu opioid receptor agonist with the D1-selective dopamine receptor agonist SKF 38393 markedly potentiates different behaviors in mice.
    Toyoshi T; Ukai M; Kameyama T
    Eur J Pharmacol; 1992 Mar; 213(1):25-30. PubMed ID: 1354161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D1 receptors function to inhibit the activation of tuberoinfundibular dopamine neurons.
    Berry SA; Gudelsky GA
    J Pharmacol Exp Ther; 1990 Aug; 254(2):677-82. PubMed ID: 1974647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonstriatal dopamine D1 receptors regulate striatal acetylcholine release in vivo.
    Acquas E; Wilson C; Fibiger HC
    J Pharmacol Exp Ther; 1997 Apr; 281(1):360-8. PubMed ID: 9103518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Independent in vitro regulation by the D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+-stimulated release of acetylcholine from rat neostriatum.
    Stoof JC; Kebabian JW
    Brain Res; 1982 Nov; 250(2):263-70. PubMed ID: 6293642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of dopamine D1 and D2 receptors on striatal acetylcholine release in rats.
    Ikarashi Y; Takahashi A; Ishimaru H; Arai T; Maruyama Y
    Brain Res Bull; 1997; 43(1):107-15. PubMed ID: 9205804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endogenous dopamine facilitates striatal in vivo acetylcholine release by acting on D1 receptors localized in the striatum.
    Consolo S; Girotti P; Russi G; Di Chiara G
    J Neurochem; 1992 Oct; 59(4):1555-7. PubMed ID: 1402904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine receptor-mediated regulation of striatal cholinergic activity: positron emission tomography studies with norchloro[18F]fluoroepibatidine.
    Ding YS; Logan J; Bermel R; Garza V; Rice O; Fowler JS; Volkow ND
    J Neurochem; 2000 Apr; 74(4):1514-21. PubMed ID: 10737608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.